Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Matinas BioPharma Holdings is a clinical-stage biopharmaceutical company developing lipid nanocrystal (LNC) platform-based therapies. Its lead product, MAT2203, is an oral antifungal designed to treat invasive fungal infections with improved safety and convenience. The company focuses on strategic partnerships, licensing, and advancing its pipeline through regulatory designations, targeting high-need markets such as invasive aspergillosis and cryptococcal meningitis.
This description was generated via AI from an annual report. Updated about 1 year ago.